Mutations of the tumor suppressor wild-type p53 gene have been implicated in the
development of resistance to anticancer drugs. We have examined the role of wild-type p53 …

We have recently reported that mutations of the tumor suppressor p53 gene are associated
with the development of resistance to cis-platinum in human ovarian cancer cells, and that …

We have examined p53 protein levels in cell lines selected for resistance to the
chemotherapeutic drug cis‐diamminedichloroplatinum (II), cisplatin. The majority of the …

Recent studies suggest that drug induced apoptosis relates to the sensitivity. p53 gene,
which has a pivotal role in inducing apoptosis, frequently mutates in ovarian cancer …

Nine human ovarian cancer cell lines that express wild-type (wt) or mutated p53 were used
to evaluate the cytotoxicity induced by paclitaxel. The IC50 calculated in the five mutated …

A new recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) was developed
and the combination effect of p53 gene transfer and cis-diamminedichloroplatinum …

Mujoo K, Catino JJ, Maneval DC, Gutterman JU. Studies on the molecular mechanism of
growth inhibition with p53 adenoviral construct in human ovarian cancer. Int J Gynecol …

Wild-type p53 is frequently mutated in late-stage ovarian cancer and has been proposed as
a determinant of cisplatin chemosensitivity. We have therefore established a human ovarian …

Cancer cells containing mutated p53 are sensitive to the re-introduction of the wild-type (wt)
p53. We sought to determine whether ovarian cancer cells that retain wt p53 are sensitive to …

The cytotoxicity of Doxorubicin and cis‐dichloro‐diammine‐platinum (DDP) was evaluated
in clones, obtained from a human ovarian cancer cell line transfected with a temperature …